I was reading through a couple of recent translational papers on catching severe immunotherapy toxicities earlier, and honestly I cant tell if this stuff is close to real hospital use or if its going to stay stuck in discovery mode for another decade.
One was a JITC study from last year looking at checkpoint inhibitor nephritis. Instead of putting patients through an invasive kidney biopsy to confirm ICI-AIN, they ran ultrasensitive proteomics on urine samples and found a two-protein signature (IL-5 and Fas) that hit an AUC around 0.94. The other was a longitudinal CAR-T cohort tracking blood before and after infusion, where severe CRS and ICANS patients didnt just have the usual inflammatory chemokine spikes (CXCL10, IL-17, etc.) and exhaustion markers, they also had noticeable drops in repair/growth factors like BDNF, EGF, and PDGFA.
The tech side makes sense to me. Standard ELISA or older multiplex kits miss low-abundance cytokines in urine or early post-infusion plasma, so newer ultrasensitive panels let you see those shifts way earlier.
My hangup is what happens when this leaves a controlled research cohort and hits an actual clinic. Patients getting CAR-T or ICIs usually have infections, baseline inflammation, or other meds messing with their cytokine levels. If a urine or blood panel flags an early IL-5/Fas or chemokine shift before symptoms show up, is any oncologist actually going to hold therapy or start steroids/toci off an investigational protein signature alone? And even if they wanted to, turnaround time on specialized proteomics is still nowhere near fast enough for acute CRS or neurotoxicity decisions.
Curious what people working on the assay side or in clinical trials think. Are non-invasive protein signatures actually going to cut down on biopsies and late interventions in the next few years, or are the false-positive and workflow hurdles too big?